The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Specifying which patients should undergo cardiovascular surveillance following lymphoma treatment
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the evolving landscape of cardiovascular surveillance in patients undergoing lymphoma treatment. He emphasizes the need for individualized approaches due to limited data on specific surveillance protocols tailored to each therapy. Dr Svoboda highlights the need for further research into therapies such as BTK inhibitors, immune checkpoint inhibitors, and CAR-T therapies to better understand their cardiovascular implications. This interview occurred at the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role: Adaptive Biotechnologies; AstraZeneca; Atara Biotherapeutics; BMS; Crispr therapeutics; Pharmacyclics; Seagen. Research Funding: Adaptive Biotechnologies (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst).
